Fennec Pharmaceuticals Inc. (FENC)

Market Cap	169.26M +1.0%
Revenue (ttm)	44.64M -6.1%
Net Income	-10.10M
EPS	-0.35
Shares Out	28.12M
PE Ratio	n/a
Forward PE	32.25
Dividend	n/a
Ex-Dividend Date	n/a

Volume	809,178
Open	6.79
Previous Close	7.45
Day's Range	5.90 - 6.97
52-Week Range	4.68 - 9.92
Beta	0.80
Analysts	Strong Buy
Price Target	15.00 (+149.17%)
Earnings Date	Mar 24, 2026

About FENC

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the ri...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 5, 2001
• Employees: 32
• Stock Exchange: NASDAQ
• Ticker Symbol: FENC
• Website: https://fennecpharma.com

Financial Performance

In 2025, Fennec Pharmaceuticals's revenue was $44.64 million, a decrease of -6.09% compared to the previous year's $47.54 million. Losses were -$10.10 million, 2216.1% more than in 2024.

Analyst Summary

According to 3 analysts, the average rating for FENC stock is "Strong Buy." The 12-month stock price target is $15.0, which is an increase of 149.17% from the latest price.

Price Target

$15.0

(149.17% upside)

Analyst Consensus: Strong Buy